Forty Seven Continues to Outperform
January 17, 2020
0
Forty Seven On December 21, 2018 Prohost picked Forty Seven (FTSV) at $16.95 adding it to its Portfolio of biotech firms with solid scientific and non-scientific fundamentals. Forty Seven develops novel checkpoint therapies to activate macrophages in the fight against cancer. The firm targets the CD47 pathway to engage macrophages in fighting tumors. Macrophages function as . . . This content is for paid subscribers. …